NASDAQ Relative Performance Snatches The Baton From S&P 500
Dr. Duru | Jun 22, 2017 06:30AM ET
AT40 = 47.1% of stocks are trading above their respective 40-day moving averages (DMAs)
AT200 = 54.7% of stocks are trading above their respective 200DMAs
VIX = 10.8 (volatility index)
Short-term Trading Call: cautiously bullish
Commentary
Like two ships passing in the night, yesterday the NASDAQ, including the PowerShares QQQ ETF (NASDAQ:QQQ), took back its advantage in the game of relative performance over the S&P 500 (SPDR S&P 500 (NYSE:SPY)). The S&P 500 lost just over a point on the day and at one point finished filling Monday’s impressive gap up. The NASDAQ started strong and stayed strong enough to return to the week’s high (a 0.8% gain).
The S&P 500 (SPY) finished reversing its impressive gap up that started the week. At least the 20-day moving average (DMA) held as uptrending support.
The NASDAQ powered its way back to the high of the week and looks poised again to recover its all-time high.
Having forgone the opportunity on Monday to lock in profits on my QQQ call options, I jumped at that same chance yesterday. The options expire Friday so I could not afford the risk of another setback. Unfortunately my likely loss on the call options on ProShares Ultra VIX Short-Term Futures (NYSE:UVXY) will exceed those profits. The volatility index, the VIX, lost 1.0% on the day while UVXY lost 2.1%.
While none of these moves – SPY, QQQ, or UVXY – are particularly notable by themselves, they stand in contrast to AT40 (T2108), the percentage of stocks trading above their respective 40DMAs. AT40 dropped from 52.8% to 47.1%, back to a 2-week low.
Adding to the warning signs were two other favorite indicators: the Australian dollar (Guggenheim CurrencyShares Australian Dollar (NYSE:FXA)) versus the Japanese yen (JPY) or AUD/JPY and Caterpillar (NYSE:CAT). I just finished applauding AUD/JPY as a confirmation of the bullish tone of the market. My favorite forex indicator cracked 200DMA support on Tuesday and the selling continued on Wednesday.
Get The News You Want
AUD/JPY is wavering right at the edge of a breakout with very bullish implications.
I did not see any news to explain Wednesday’s sudden high-volume 3.3% loss. Perhaps it was a much delayed reaction to May’s retail data reported on Tuesday? Until proven innocent, I am interpreting CAT’s selling as bearish. I already have one put option in place, but I probably need a lot more soon.
Caterpillar (CAT) suddenly tumbles from a near 3-year high.
Some of the usual suspects were at work contributing to the weakness in AT40 – retail, energy, and mid-caps. Some auto-related stocks and shoe retailers cowered in the center of retail ugliness yesterday.
Carmax, Inc. (NYSE:KMX) reported strong headline earnings. In response, the stock gapped up and gained over 7% at its high. After that, the stock completely imploded.
In an earlier post I noted I was going to look for a post-earnings excuse to get short KMX again. However, based on the open, I thought KMX could rally to a 10% gain or higher. So I failed to pull the trigger until KMX bounced off its low of the day toward 200DMA resistance. Even then, I took half a position and bought a call option as a hedge.
Carmax (KMX) displayed one of the ugliest post-earnings gap and crap I can imagine. Its implosion form the high of the day plunged the stock back through its 50 and 200DMAs. The stock barely avoided a loss for the day!
KMX managed to close in the green, but auto parts stocks were not so lucky. For example, Autozone (NYSE:AZO) lost 1.9% and closed at a near 2 1/2 year low. The daily chart shows how pesky Amazon.com (NASDAQ:AMZN) rumors presaged the current troubles (AMZN is like a phantom looming menacingly in retail’s shadows!); AZO is down 22% since then.
Autozone (AZO) is down 27% year-to-date…
Autozone (AZO) gained about 6x post-recession. It is now up 4x after spending 2016 forming a rounded top.
Footlocker (NYSE:FL) led the way down for shoe retailers as Goldman Sachs released a report claiming that Nike (NYSE:NKE) is close to signing a direct distribution deal with Amazon. FL was down around 10% at its lows before buyers stepped up. Given FL’s existing troubles, I expect the selling to resume in due course. Note that while FL has lost 39% since mid-May, the stock is still on an incredible post-recession run after trading in the low single digits at one point!
The change in sentiment on Foot Locker (FL) is very clear as a severe breakdown continues apace.
Last month, Best Buy (NYSE:BBY) was providing some anti-Amazon hope for retail. After earnings, BBY rocketed up to an all-time high, and I noted the irony given how often BBY was supposed to be doomed by competition from AMZN. Yet, BBY failed to maintain the momentum. The post-earnings rule to fade BBY at the open is now up 3.9%. I think a test of uptrending 50DMA support is coming if not an outright gap fill. Note carefully how volume fell off a cliff over the past three days: a 50DMA test could be a major buying opportunity.
Did Best Buy (BBY) leave its best days behind?
Intel (NASDAQ:INTC) is falling behind the big cap tech pack. My last tranche of the “between earnings trade” looks like a complete bust as INTC this week confirmed a 50/200DMA breakdown and even gapped down yesterday. Analysts have come after INTC with downgrades. I do not know what to make of this beating, but I suspect I might try a pre-earnings play next month.
Intel (INTC) is down 4.7% year-to-date and has proven unable to hold 50/200DMA support for long.
The mood is very different in the biotech sector. The iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) rocketed 4.1% yesterday on a second day of very high buying volume. IBB is above its price of every single “bash” except Hillary Clinton’s first campaign-related bash from almost two years ago. IBB finally looks poised to overcome that last hurdle.
This week, the iShares Nasdaq Biotechnology (IBB) broke out from almost 18 months worth of consolidation patterns.
If current rumors are true, IBB should trade above all the recent bashes. Apparently, the drug price plan coming from the Trump administration will fall far short of Trump’s campaign and presidential promises. The rumors are apparently coming to a climax this week after a report from Politico titled “Trump’s drug price ‘remedy’ expected to be industry friendly ” last Friday. From the article:
“The administration is not proposing, as Trump did on the campaign trail, that the government negotiate drug prices or allow the importation of cheaper drugs from abroad. At a meeting Friday, top Trump administration officials reportedly made little progress on even on more modest goals that are said to be an executive order on drug prices, which the White House is pushing to release…
‘Our industry sources indicate that pharma expects it has successfully shifted the dialogue from the high price of innovation to transparency and other parts of the supply chain,’ Wells Fargo analyst David Maris wrote in a note to investors Thursday evening. ‘As such, several drug company executives have expressed the belief that Trump’s drug price approach will not include drug re-importation and Medicare negotiation of drug prices.’
The industry’s growing confidence comes in part from the presence of key allies in the White House: Joe Grogan, OMB’s director of health programs, is working on the executive order, according to multiple sources inside and outside of the government. Grogan spent the last five years as the head of federal affairs for Gilead Sciences (NASDAQ:GILD) — the drug company that helped ignite the drug pricing debate in 2013, when it set the price of a new hepatitis C treatment at more than $80,000.”
Buying IBB in the wake of THAT article would have made for a great Trump Trade.
Daily AT40 (T2108)
Black line: AT40 (T2108) (% measured on the right)
Red line: Overbought threshold (70%); Blue line: Oversold threshold (20%)
Weekly AT40 (T2108)
*All charts created using freestockcharts.com unless otherwise stated
The charts above are my LATEST updates independent of the date of this given AT40 post.
Full disclosure: long INTC call options, short KMX, long KMX call option, long CAT put option, short AUD/JPY, long FL put spread and call options, long AMZN call option, long GS call options
*Charting notes: FreeStockCharts.com uses midnight U.S. Eastern time as the close for currencies.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.